文献速递头颈部肿瘤放疗姑息放疗与转移瘤

接受放射治疗的头颈部癌症患者抑郁和焦虑症状的患病率:纵向研究的系统综述与荟萃分析

Prevalence of depressive and anxiety symptoms in patients with head and neck cancer undergoing radiotherapy: A systematic review and meta-analysis of longitudinal studies.
PubMed 文献 · Radiother Oncol · 2024-11-24

该系统综述与荟萃分析纳入18项纵向研究、共1920例接受根治性放疗的头颈部癌症患者,评估放疗前、放疗后短期(≤3个月)和长期(≥6个月)抑郁与焦虑症状的合并患病率。放疗后短期内抑郁症状患病率升至26.1%,长期降至16.4%;焦虑症状从基线29.9%持续降至长期17.4%。作者认为放疗前、中、后尤其放疗后即刻进行筛查和干预有益。

要点

  • 放疗前抑郁症状合并患病率为18.1%,放疗后短期(≤3个月)升至26.1%,长期(≥6个月)降至16.4%。
  • 焦虑症状从基线合并患病率29.9%持续下降至长期17.4%。
  • 女性和已婚患者抑郁症状患病率更高,接受手术者焦虑症状患病率更低。

核心结论

  • 接受放疗的头颈部癌症患者从基线至长期随访中,临床显著抑郁和焦虑症状的患病率均较高。
  • 完成放疗后的数周是关键时期,此期间抑郁症状升高。
  • 作者认为在放疗前、放疗期间、尤其放疗后即刻进行筛查和干预将有益。

研究设计与样本

  • 遵循PROSPERO/MOOSE规范并预先注册(PROSPERO:CRD42023441432)的系统综述与荟萃分析。
  • 检索数据库建库至2024年11月1日,纳入纵向报告接受根治性放疗的头颈部癌症患者的研究。
  • 共纳入18项研究,总样本1920例,平均年龄59.9岁(SD=3.17),女性占22.2%,白种人占93.0%。
  • 采用随机效应荟萃分析估计不同治疗时间点间临床显著焦虑和抑郁症状的合并患病率与比值比。

主要发现

  • 放疗前抑郁症状合并患病率为18.1%(95%CI=13.1%-24.4%)。
  • 完成放疗后短期(≤3个月)抑郁症状患病率峰值升至26.1%(95%CI=18.9%-35.0%)。
  • 长期(≥6个月)评估时抑郁症状患病率降至16.4%(95%CI=12.6%-21.0%)。
  • 焦虑症状从基线合并患病率29.9%(95%CI=27.3%-32.7%)持续下降至长期17.4%(95%CI=12.1%-24.5%)。
  • 女性和已婚患者抑郁症状患病率更高,接受手术者焦虑症状患病率更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Patients with head and neck cancer (HNC) are particularly vulnerable to mental health concerns. Radiotherapy (RT) remains a key treatment modality for these malignancies, offering high chances of cure. However, the effects on mental health are not well defined. We aim to characterize longitudinally the prevalence and risk of depressive and anxiety symptoms over the course of RT in patients with HNC. MATERIAL AND METHODS: A literature search was performed from database inception until November 1st, 2024. PROSPERO/MOOSE-compliant and pre-registered (PROSPERO:CRD42023441432) systematic review identified studies longitudinally reporting in patients with HNC undergoing curative intent RT. Pooled prevalence and odds ratio of clinically significant anxiety and depressive symptoms between different treatment timepoints were estimated using random-effects meta-analysis. RESULTS: 18 studies (total sample 1,920, mean age 59.9[SD = 3.17], 22.2 % female, 93.0 % white ethnicity) were included. Before RT, a pooled prevalence of depressive symptoms of 18.1 % (95 % confidence intervals [CI] = 13.1 %-24.4 %) was found. Short-term after completing RT (≤3 months), the prevalence of depressive symptoms peaked to 26.1 % (95 %CI = 18.9 %-35.0 %), decreasing in long-term (≥6 months) assessments to 16.4 % (95 %CI = 12.6 %-21.0 %). Anxiety symptoms continuously decreased from baseline (pooled prevalence 29.9 % [95 %CI = 27.3 %-32.7 %]) to 17.4 % (95 %CI = 12.1 %-24.5 %) in the long-term. Female and married patients showed higher prevalence of depressive symptoms. Those who underwent surgery showed a lower prevalence of anxiety symptoms. CONCLUSIONS: High prevalence of clinically significant depressive and anxiety symptoms were found in patients with HNC undergoing RT, from baseline to long-term follow-up. The weeks following completion of RT are key, as depressive symptoms increase in this period. Screening and interventions prior to, during, and especially immediately post-RT would be beneficial.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Jiménez-Labaig P, Aymerich C, Rullan A, et al. Prevalence of depressive and anxiety symptoms in patients with head and neck cancer undergoing radiotherapy: A systematic review and meta-analysis of longitudinal studies. Radiother Oncol. 2024. PMID: 39586358. doi:10.1016/j.radonc.2024.110649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。